Company intelligence / Profile preview
Viking Therapeutics
San Diego, California, United Statesvikingtherapeutics.com ↗
- Ownership
- Public · VKTX
- Employees
- ~41
- Development stage
- Phase 2
01
Overview
Viking Therapeutics has demonstrated strong clinical results with its lead programs. VK2735, a dual GLP‑1/GIP agonist for obesity, showed up to ~14% weight loss in a Phase II trial and will enter Phase III in H1'2025. An oral version of VK2735 also showed promising efficacy (~8% weight loss in four weeks post-treatment). VK2809 met primary/secondary endpoints in a large Phase IIb NASH study with significant reductions in liver fat and LDL-C. VK0214 reduced very long-chain fatty acids safely in X‑ALD patients during early trials.
- Therapeutic areas
- GastroenterologyEndocrinologyRare Diseases
- Modalities
- Small molecules (e.g., selective thyroid hormone receptor beta agonists)Peptides (e.g., dual GLP‑1/GIP receptor agonists)Dual amylin and calcitonin receptor agonists (DACRAs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $3.8B
- Total revenue
- $0
- Enterprise value
- $3.3B
Beyond the preview
Go deeper on Viking Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viking Therapeutics.